Next Article in Journal
Circulating Levels of Osteopontin Predict Patients’ Outcome after Resection of Colorectal Liver Metastases
Next Article in Special Issue
Lipid Myopathies
Previous Article in Journal
Propensity Score-Matched Analysis of the Survival Benefit from Kidney Transplantation in Patients with End-Stage Renal Disease

Mitochondrial Neurogastrointestinal Encephalomyopathy (MNGIE-MTDPS1)

Center for Neuromuscular Diseases, Unit of Neurology, ASST Spedali Civili and University of Brescia, 25100 Brescia, Italy
Department of Neuroscience, Unit of Neurology, Azienda Ospedaliera Universitaria Integrata Verona, 37100 Verona, Italy
Author to whom correspondence should be addressed.
J. Clin. Med. 2018, 7(11), 389;
Received: 2 October 2018 / Revised: 14 October 2018 / Accepted: 24 October 2018 / Published: 26 October 2018
(This article belongs to the Special Issue Advances in Metabolic Myopathies)
Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE-MTDPS1) is a devastating autosomal recessive disorder due to mutations in TYMP, which cause a loss of function of thymidine phosphorylase (TP), nucleoside accumulation in plasma and tissues, and mitochondrial dysfunction. The clinical picture includes progressive gastrointestinal dysmotility, cachexia, ptosis and ophthalmoparesis, peripheral neuropathy, and diffuse leukoencephalopathy, which usually lead to death in early adulthood. Other two MNGIE-type phenotypes have been described so far, which are linked to mutations in POLG and RRM2B genes. Therapeutic options are currently available in clinical practice (allogeneic hematopoietic stem cell transplantation and carrier erythrocyte entrapped thymidine phosphorylase therapy) and newer, promising therapies are expected in the near future. Since successful treatment is strictly related to early diagnosis, it is essential that clinicians be warned about the clinical features and diagnostic procedures useful to suspect diagnosis of MNGIE-MTDPS1. The aim of this review is to promote the knowledge of the disease as well as the involved mechanisms and the diagnostic processes in order to reach an early diagnosis. View Full-Text
Keywords: MNGIE; MTDPS1; mitochondrial diseases; mitochondrial therapy; mitochondrial neurogastrointestinal encephalopathy MNGIE; MTDPS1; mitochondrial diseases; mitochondrial therapy; mitochondrial neurogastrointestinal encephalopathy
Show Figures

Figure 1

MDPI and ACS Style

Filosto, M.; Cotti Piccinelli, S.; Caria, F.; Gallo Cassarino, S.; Baldelli, E.; Galvagni, A.; Volonghi, I.; Scarpelli, M.; Padovani, A. Mitochondrial Neurogastrointestinal Encephalomyopathy (MNGIE-MTDPS1). J. Clin. Med. 2018, 7, 389.

AMA Style

Filosto M, Cotti Piccinelli S, Caria F, Gallo Cassarino S, Baldelli E, Galvagni A, Volonghi I, Scarpelli M, Padovani A. Mitochondrial Neurogastrointestinal Encephalomyopathy (MNGIE-MTDPS1). Journal of Clinical Medicine. 2018; 7(11):389.

Chicago/Turabian Style

Filosto, Massimiliano, Stefano Cotti Piccinelli, Filomena Caria, Serena Gallo Cassarino, Enrico Baldelli, Anna Galvagni, Irene Volonghi, Mauro Scarpelli, and Alessandro Padovani. 2018. "Mitochondrial Neurogastrointestinal Encephalomyopathy (MNGIE-MTDPS1)" Journal of Clinical Medicine 7, no. 11: 389.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop